Adaptimmune Therapeutics PLC
ADAP0.055USD
0.0000.00%
交易中 （美东）报价延迟15分钟
87.31M总市值
亏损市盈率 TTM
关于 Adaptimmune Therapeutics PLC 公司
Adaptimmune Therapeutics PLC is focused on pre-clinical programs, including PRAME and CD70-directed T-cell therapies, and its allogeneic pipeline. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). It is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.
Adaptimmune Therapeutics PLC简介
公司代码ADAP
公司名称Adaptimmune Therapeutics PLC
上市日期May 06, 2015
CEORawcliffe (Adrian George)
员工数量506
证券类型Depository Receipt
年结日May 06
公司地址60 Jubilee Avenue
城市ABINGDON
上市交易所NASDAQ Capital Market Consolidated
国家United Kingdom
邮编OX14 4RX
电话441235430000
网址https://www.adaptimmune.com/
公司代码ADAP
上市日期May 06, 2015
CEORawcliffe (Adrian George)
Adaptimmune Therapeutics PLC公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
611.22K
+401293.00%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Non-Executive Independent Director
Non-Executive Independent Director
23.89K
--
Mr. Adrian Rawcliffe
Mr. Adrian Rawcliffe
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. William C. (Bill) Bertrand, Jr., Esq.
Mr. William C. (Bill) Bertrand, Jr., Esq.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. John P. Furey
Mr. John P. Furey
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Kristen M. Hege, M.D.
Dr. Kristen M. Hege, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Andrew Allen, M.D., Ph.D.
Dr. Andrew Allen, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Priti Hegde, Ph.D.
Dr. Priti Hegde, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
611.22K
+401293.00%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Non-Executive Independent Director
Non-Executive Independent Director
23.89K
--
Mr. Adrian Rawcliffe
Mr. Adrian Rawcliffe
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. William C. (Bill) Bertrand, Jr., Esq.
Mr. William C. (Bill) Bertrand, Jr., Esq.
Chief Operating Officer
Chief Operating Officer
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 2月4日 周三
更新时间: 2月4日 周三
持股股东
股东类型
持股股东
持股股东
占比
Long Focus Capital Management LLC
7.01%
Renaissance Technologies LLC
1.53%
Morgan Stanley & Co. LLC
1.38%
Jane Street Capital, L.L.C.
1.06%
Acadian Asset Management LLC
0.56%
其他
88.47%
持股股东
持股股东
占比
Long Focus Capital Management LLC
7.01%
Renaissance Technologies LLC
1.53%
Morgan Stanley & Co. LLC
1.38%
Jane Street Capital, L.L.C.
1.06%
Acadian Asset Management LLC
0.56%
其他
88.47%
股东类型
持股股东
占比
Hedge Fund
8.54%
Research Firm
2.99%
Investment Advisor/Hedge Fund
0.84%
Investment Advisor
0.81%
Individual Investor
0.63%
Pension Fund
0.05%
Venture Capital
0.04%
其他
86.10%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
164
35.18M
13.27%
-124.88M
2025Q3
183
42.26M
58.51%
-57.25M
2025Q2
189
116.07M
65.05%
-1.37M
2025Q1
186
117.46M
62.78%
-44.42M
2024Q4
186
127.90M
58.86%
-11.67M
2024Q3
189
154.60M
64.35%
-2.20M
2024Q2
192
156.54M
67.34%
-7.97M
2024Q1
203
164.83M
67.18%
-6.80M
2023Q4
199
145.59M
71.95%
-5.54M
2023Q3
217
150.77M
70.44%
+3.59M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Long Focus Capital Management LLC
18.58M
7.01%
-5.18M
-21.80%
Sep 30, 2025
Renaissance Technologies LLC
4.05M
1.53%
+2.17M
+115.32%
Sep 30, 2025
Morgan Stanley & Co. LLC
3.65M
1.38%
-568.56K
-13.48%
Sep 30, 2025
Jane Street Capital, L.L.C.
2.81M
1.06%
+2.81M
--
Sep 30, 2025
Acadian Asset Management LLC
1.49M
0.56%
-478.99K
-24.39%
Sep 30, 2025
BofA Global Research (US)
1.32M
0.5%
+177.96K
+15.59%
Sep 30, 2025
Alpha Architect, LLC
800.00K
0.3%
--
--
Sep 30, 2025
Menzel (Garry E)
611.22K
0.23%
+401.29K
+191.15%
Apr 11, 2025
B. Riley Wealth Advisors, Inc.
500.00K
0.19%
+500.00K
--
Sep 30, 2025
Rathbones Investment Management Limited
432.82K
0.16%
--
--
Sep 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
ActivePassive International Equity ETF
0%
Fidelity Enhanced Small Cap ETF
0%
SPDR S&P International Small Cap ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
ActivePassive International Equity ETF
占比0%
Fidelity Enhanced Small Cap ETF
占比0%
SPDR S&P International Small Cap ETF
占比0%
Invesco NASDAQ Future Gen 200 ETF
占比0%
SPDR Portfolio Developed World ex-US ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
除权除息日
类型
比率
暂无数据
公告日期
除权除息日
类型
比率
暂无数据
